StockMacro
Company, fund or insider

Help

Menu

BioStem Technologies

$0.64 -84% in 6 monthsMarket cap $12.2M

BSEM on XNAS, Health Care, BioStem Technologies, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 84% in a year as latest quarter revenue dropped 27% to $7.6M.

  • BadTwo share registrations S-1 and two private offerings in 90 days
  • WatchCompanies filing S-1 trailed sector by median 23.8 points over six months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
2
Website
biostemtechnologies.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
no estimate
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $7.6M, net loss $11.4M.
Quarter to 30 Jun 2025: revenue $11.0M, net income $11KQuarter to 30 Jun 2025: revenue $11.0M, net income $11KQuarter to 30 Sep 2025: revenue $10.5M, net income $761KQuarter to 30 Sep 2025: revenue $10.5M, net income $761KQuarter to 30 Jun 2026: revenue $7.9M, net income -$9.0MQuarter to 30 Jun 2026: revenue $7.9M, net income -$9.0MQuarter to 30 Sep 2026: revenue $7.6M, net income -$11.4MQuarter to 30 Sep 2026: revenue $7.6M, net income -$11.4M
30 Jun 2025RevenueNet incomeNet losstallest bar $11.4M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$7.6M-$11.4M
30 Jun 2026$7.9M-$9.0M
30 Sep 2025$10.5M$761K
30 Jun 2025$11.0M$11K
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. – –
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $971K $27.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $1.0M –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $29K –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.05 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.96
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. – 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.66 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
BioStem TechnologiesBSEM (this company) $12.2M––––
BioCardiaBCDA $11.9Mloss–––
Passage BioPASG $12.6Mloss–––
Dyadic InternationalDYAI $11.5Mloss3.7-7.6%-227%
Acumen PharmaceuticalsABOS $13.5Mloss–––
PluriPLUR $13.5Mloss9.3+10%–

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-27%

$7.6M vs $10.5M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-100%

$0 vs $2.4M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$14K

bought $0, sold $14K

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

9.1%

1.7M shares held by 13F filers (30 Sep 2026) of 19.2M outstanding (11 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.5%

287K shares sold short (30 Oct 2026) of 19.2M outstanding (11 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.5

287K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-14%

334K shares sold short in the report before, 287K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

36%

36% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 54%

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$300K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

4

4 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

2.0×

4 articles in the last 7 days; its usual week has 2.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 554K, 2.4× a year earlier

Price $0.64 on 20 Nov 2026, -84% over 12 months (12-month range $0.64 to $8.20)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $14K in the last 12 months (the 12 months before: $0).
Revenue per quarter. Revenue $7.6M in the latest quarter, -27% on a year earlier.
Capital spending per quarter. Capital spending $0 in the latest quarter, -100% on a year earlier.
Institutional holders (13F filers). 23 13F filers reported holding it in the latest 13F quarter, 0% on a year earlier.
Lobbying spend. Lobbying spend: $300K published in the last 12 months, -23% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
9 Oct 20268-K and other filingsPrivate placement of securities (Form D)
2 Oct 20268-K and other filingsRegistered new securities for sale (S-1)
21 Sep 20268-K and other filingsPrivate placement of securities (Form D)
18 Sep 20268-K and other filingsRegistered new securities for sale (S-1)
1 Sep 2026Sharp changeShort interest spike: short interest spike, 554K vs usual 378K (2026-08-14); 2.4x the same period a year earlier
7 Aug 20268-K and other filingsRegistered new securities for sale (S-1)
29 Jul 20268-K and other filingsRegistered new securities for sale (S-1)
20 Jul 2026Lobbying filinglobbying engagement terminated (BALLARD PARTNERS)
3 Jun 20268-K and other filingsPrivate placement of securities (Form D)
16 Sep 2024Lobbying filingnew lobbying registration (BALLARD PARTNERS)
16 Sep 2024Sharp changeFirst lobbying registration: first lobbying registration: BIOSTEM TECHNOLOGIES: new lobbying registration (BALLARD PARTNERS)
4 Apr 20238-K and other filingsPrivate placement of securities (Form D)
Insider net buying (open market)
Month from 1 Nov 2026: -$14K published
Revenue per quarter
Quarter ended 30 Jun 2025: $11.0M; public on 13 Aug 2026
Quarter ended 30 Sep 2025: $10.5M; public on 13 Nov 2026
Quarter ended 30 Jun 2026: $7.9M, -28% on a year earlier; public on 13 Aug 2026
Quarter ended 30 Sep 2026: $7.6M, -27% on a year earlier; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 30 Sep 2025: $2.4M; public on 13 Nov 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
30 Sep 2026 report: 23; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Oct 2024: $80K published
Quarter from 1 Jan 2025: $80K published
Quarter from 1 Apr 2025: $80K published
Quarter from 1 Jul 2025: $110K published
Quarter from 1 Oct 2025: $120K published
Quarter from 1 Jan 2026: $120K published
Quarter from 1 Apr 2026: $120K published
Quarter from 1 Jul 2026: $60K published

What is unusual now

  • Made public in the last 90 days: it had 554K shares sold short in the 14 Aug 2026 report, 2.4× the same report last year.
  • Short interest spike: had 554K shares sold short in the 14 Aug 2026 report, 2.4× the same report last year Public on 26 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $14K in the last 12 months (the 12 months before: $0).
  • Revenue per quarter: Revenue $7.6M in the latest quarter, -27% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 1 insider trades

Last 90 days: 1 sale, $14K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Nov 2026Jason MatuszewskiChief Executive OfficerSell14,300$1.00$14KForm 4

23 institutions reported shares at the end of Q3 2026, 9% of the shares outstanding; 23 opened a position, 0 sold out. From 13F reports.

InstitutionShares% of companyValueChange
PNC Financial Services Group, Inc.544K2.84%$1.7M
Vanguard Capital Management LLC485K2.53%$1.5M
Anson Funds Management LP368K1.92%$1.2M
Geode Capital Management, LLC141K0.74%$437K
Vanguard Fiduciary Trust Co82K0.43%$253K
Northern Trust Corp33K0.17%$103K
Millennium Management LLC24K0.13%$74K
UBS Group AG20K0.10%$62K
Virtu Financial LLC19K0.10%
StoneX Group Inc.18K0.10%$61K

Company events

All 13 company events

In 12 months: 4 share registrations, 3 private placements, 2 major agreements. Results releases and routine reports are left out.

FiledWhat happenedSource
9 Oct 2026Private placement of securities (Form D)$3.0M sold of $3.0M offeredD
2 Oct 2026Registered new securities for sale (S-1)S-1
30 Sep 2026Signed a major agreementSame filing: sold shares privately8-K
21 Sep 2026Private placement of securities (Form D)$0 sold of $40.0M offeredD
18 Sep 2026Signed a major agreementSame filing: sold shares privately8-K
18 Sep 2026Registered new securities for sale (S-1)S-1
7 Aug 2026Registered new securities for sale (S-1)S-1/A
29 Jul 2026Registered new securities for sale (S-1)S-1

Reported lobbying spend: $60K in Q2 2026, $120K in Q1 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
12 May 2026EndedBallard Partnersfor Biostem TechnologiesAdvocated for medicare reimbursement for skin substitutes that are used to heal wounds caused from diabetes.Medicare/MedicaidFiling
1 Aug 2024NewBallard Partnersfor Biostem TechnologiesAdvocated for medicare reimbursement for skin substitutes that are used to heal wounds caused from diabetes.Medicare/MedicaidFiling

The 5 newest of 84 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 9 Oct 2026Filings record

    Private placement of securities (Form D)

  2. 2 Oct 2026Filings record

    Registered new securities for sale (S-1)

  3. 21 Sep 2026Filings record

    Private placement of securities (Form D)

  4. 18 Sep 2026Filings record

    Registered new securities for sale (S-1)

  5. 26 Aug 2026Short interest and volume change

    had 554K shares sold short in the 14 Aug 2026 report, 2.4× the same report last year.

    Same report last year: 234K; its normal report is 378K.

    See the evidence
    This period
    554K (the 14 Aug 2026 report)
    Normal report (median of 24 earlier)
    378K
    Typical spread (median absolute deviation)
    30K
    How far from its usual level
    +3.5
    Same report last year
    234K
    History used
    3,150 days
    2025-08-15: 234K2025-08-29: 173K2025-09-15: 178K2025-09-30: 208K2025-10-15: 230K2025-10-31: 241K2025-11-14: 311K2025-11-28: 315K2025-12-15: 310K2025-12-31: 302K2026-01-15: 307K2026-01-30: 406K2026-02-13: 383K2026-02-27: 401K2026-03-13: 410K2026-03-31: 395K2026-04-15: 375K2026-04-30: 381K2026-05-15: 390K2026-05-29: 383K2026-06-15: 383K2026-06-30: 383K2026-07-15: 390K2026-07-31: 392K2026-08-14: 554K
    the 14 Aug 2026 report24 earlier reportsnormal: 378K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 7 Aug 2026Filings record

    Registered new securities for sale (S-1)

  7. 29 Jul 2026Filings record

    Registered new securities for sale (S-1)

  8. 20 Jul 2026Lobbying record

    BIOSTEM TECHNOLOGIES: lobbying engagement terminated (BALLARD PARTNERS) (dated 12 May 2026)

  9. 3 Jun 2026Filings record

    Private placement of securities (Form D)

  10. 16 Sep 2024Lobbying change

    registered for federal lobbying for the first time in our data (Ballard Partners).

    See the evidence (1 source record)
    Source coverage starts
    2 Jan 2009
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  11. 16 Sep 2024Lobbying record

    BIOSTEM TECHNOLOGIES: new lobbying registration (BALLARD PARTNERS) (dated 1 Aug 2024)

  12. 4 Apr 2023Filings record

    Private placement of securities (Form D)

  13. 25 May 2021Filings record

    Private placement of securities (Form D)

  14. 16 Aug 2016Filings record

    Private placement of securities (Form D)

  15. 1 Feb 2016Filings record

    Private placement of securities (Form D)

Not listed: 9 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001658678
Ticker
BSEM
Domain
biostemtechnologies.com
Employer name
Biostem Technologies (1 unverified)
Fein
27-0400416 (1 unverified)
Hq location
FL|POMPANO BEACH|33604 (1 unverified)
Lobbying client
biostem technologies
Name
BioStem Technologies, Inc.
  • DOL H-1B labor condition applications and PERM certifications2 data points6 Apr 2026 to 6 Apr 2026
  • Federal lobbying disclosures (LDA)2 records, 24 data points1 Aug 2024 to 30 Jun 2026
  • SEC Form 13F institutional holdings9 data points30 Sep 2026 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)19 records1 Feb 2016 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)62 data points31 Dec 2024 to 11 Nov 2026
  • SEC Form 4 insider transactions1 record, 4 data points19 Nov 2026 to 19 Nov 2026
  • FINRA short interest (twice monthly)539 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)150 data points7 Aug 2026 to 20 Nov 2026